Modality
ASO
MOA
WRNi
Target
IL-23
Pathway
Autophagy
RCCPTSD
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
~Sep 2017
→ ~Dec 2018
Phase 2
Mar 2019
→ May 2027
Phase 2Current
NCT07488268
2,658 pts·RCC
2023-08→TBD·Active
NCT06571900
2,900 pts·RCC
2019-03→2027-05·Recruiting
5,558 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-05-101.1y awayPh2 Data· RCC
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2
Recruit…
P2
Active
Catalysts
Ph2 Data
2027-05-10 · 1.1y away
RCC
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07488268 | Phase 2 | RCC | Active | 2658 | PASI75 |
| NCT06571900 | Phase 2 | RCC | Recruiting | 2900 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ |